An anonymized planning case and practical guide. The correspondence available for this article documents a family's intention to seek evaluations in Shanghai. It does not establish that the patient has traveled, attended consultations, qualified for a trial, or received treatment in China. This article does not provide medical advice.
A family whose mother is receiving care at Dana-Farber Cancer Institute in the United States approached a Shanghai medical concierge service with a focused question: could specialists in Shanghai identify a realistic investigational pathway for her metastatic pancreatic ductal adenocarcinoma before the family committed to travel? Her records included pathology, molecular testing showing KRAS G12D, high-resolution HLA typing, recent scans, laboratory results, and a treatment history. She was receiving an investigational KRAS-pathway therapy in the United States. Those facts make a specialist review worth exploring; they do not, by themselves, establish eligibility for TCR-T, another cellular therapy, or any clinical trial.
Start with a decision, not a hospital list
The family's immediate decision was whether a trip to Shanghai could lead to a meaningful in-person evaluation. A useful pre-travel review should identify which clinical questions can be assessed from records, which institutions or teams may be appropriate to contact, what additional tests might be required, and what cannot be determined without seeing the patient. Interest in reviewing a file is not an offer of trial enrollment.
Step 1: Obtain permission and assemble the record
Before sharing medical information across institutions or borders, obtain the patient's authorization and agree on who may receive the records. Prepare a concise English case summary alongside the complete source documents:
- Pathology report and, if requested by a receiving team, information on the availability of tissue or slides.
- FoundationOne or other molecular reports, the KRAS G12D result, and the original high-resolution HLA report.
- Recent CT or MRI reports and original DICOM image files, with scan dates clearly labeled.
- Recent laboratory results, functional status, current medications, and relevant medical history.
- A chronological treatment record showing drugs, dates, responses, progression, and any significant adverse effects.
Ask the treating team in the United States to help confirm that the summary reflects the current clinical situation. Do not stop, delay, or change an existing treatment on the basis of a coordinator's preliminary discussion.
Step 2: Define the questions for each Shanghai consultation
Ruijin Hospital, a relevant Fudan University Shanghai Cancer Center or affiliated research team, and any Gaobo team under consideration should be approached as separate potential consultations, not presented as a single coordinated program. For background on individual specialists, see our profiles of Prof. Shen Baiyong at Ruijin, Prof. Yu Xianjun at Fudan University Shanghai Cancer Center, and Dr. Zhou Jun at Gaobo. These profiles are background reading, not confirmation that any of these doctors has reviewed this patient's case. The exact Gaobo institution, Fudan hospital, department, physician, and appointment pathway should be verified before travel. For each team, ask: What is the clinical objective of the consultation? Which records should be submitted first? Is a preliminary record review possible? Which potential options are being evaluated? What additional testing or in-person assessment would be needed?
For any proposed trial, request the study identifier, participating site, current recruitment status, main eligibility and exclusion criteria, and the name of the research contact who can confirm the next screening step. A mutation or HLA match alone does not prove that a patient qualifies. Prior therapies, measurable disease, organ function, timing, and other protocol-specific requirements may matter.
Step 3: Treat remote feedback as triage, not approval
With the patient's permission, a coordinator can organize the dossier, help route questions to appropriate offices, clarify appointment requirements, and relay responses accurately. A physician's remote review, where available and authorized by that physician, can help prioritize the trip. It cannot replace a formal consultation, informed consent, required examinations, or a trial team's eligibility decision. Record the precise wording of every response: “records received,” “in-person assessment recommended,” and “eligible for screening” mean different things.
Step 4: Run each in-person consultation consistently
Bring the same up-to-date summary and original records to each appointment. After each visit, capture the date, institution, clinician and specialty, materials reviewed, assessment, proposed next steps, tests requested, and follow-up contact. Ask whether the team is recommending standard care, an investigational study, additional diagnostic work, or simply a second opinion. If a research pathway is discussed, ask what would happen next and who makes the formal screening decision.
Interpretation and administrative support can help the family ask the same questions at each visit and avoid losing important details between appointments. Medical decisions remain with the treating clinicians and the patient.
Step 5: Compare the answers before choosing a path
A side-by-side comparison is more useful than collecting impressive names. For every recommendation, note its treatment goal, supporting rationale, outstanding eligibility conditions, potential risks, expected timing, travel requirements, and compatibility with the U.S. treatment plan. Where specialists disagree, ask what clinical evidence or additional test would resolve the difference. Send the resulting medical opinions back to the patient's U.S. oncology team before deciding whether to pursue further evaluation in Shanghai.
Practical checklist for families
- Get the patient's authorization before transferring records.
- Prepare both a one-page summary and complete, dated source documents.
- Verify the exact hospital, doctor, research site, and appointment process.
- Separate a preliminary review from formal trial screening and enrollment.
- Confirm the scope and fees of coordination services before paid work begins.
- Keep the U.S. treating team informed throughout the process.
What this case can and cannot show
This family's inquiry illustrates a disciplined way to explore a cross-border second opinion: organize the evidence, ask narrow questions, seek separate specialist assessments, and compare actionable next steps. The information currently available does not establish that consultations at Ruijin, Gaobo, or a Fudan-affiliated institution have happened, nor does it support any claim of trial acceptance or a treatment outcome. If those visits take place, a future case report should be updated only from verified consultation records and with the patient's consent.
CMCS is a medical concierge and health-management company, not a hospital. We can help families organize records and coordinate appropriate inquiries and visits; physicians and research teams make all clinical and trial decisions.
For coordination inquiries: contract@medicalsh.com | WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
0件のコメント